Keyphrases
Programmed Death-ligand 1 (PD-L1)
100%
Gastric Cancer
100%
Dynamic Expression
100%
ImmunoPET
100%
Heterogeneous Expression
100%
Glycosylation
44%
Avelumab
44%
Positron Emission Tomography
33%
Programmed Death-ligand 1 Expression
33%
Atezolizumab
33%
Gastric Cancer Cells
33%
Tumor
22%
Binding Affinity
22%
Spatial Heterogeneity
22%
Anti-programmed Death 1
22%
PNGase F
22%
Patient-derived Xenograft
11%
Immunofluorescence
11%
FDA-approved Drugs
11%
Cancer Model
11%
Tissue Sampling
11%
Western Blot Analysis
11%
O-glycosylation
11%
Binding Assay
11%
Binding Studies
11%
Ex Vivo Biodistribution
11%
Immunofluorescence Microscopy
11%
Antibody Recognition
11%
1-form
11%
Anti-programmed death-1 Monoclonal Antibody
11%
Spatially Heterogeneous
11%
Gastric Tumor
11%
Antibody Uptake
11%
Spatial Binding
11%
Cancer Cell Heterogeneity
11%
Biochemistry, Genetics and Molecular Biology
Glycosylation
100%
Cancer Cell
75%
Positron Emission Tomography
75%
Immunofluorescence
50%
Binding Affinity
50%
Dynamics
25%
Western Blot
25%
Deglycosylation
25%
Molecular Weight
25%
Biodistribution
25%
Binding Study
25%
Cancer Model
25%
Immunology and Microbiology
Programmed Death 1 Ligand 1
100%
Glycosylation
28%
Avelumab
28%
Positron Emission Tomography
21%
Cancer Cell
21%
Atezolizumab
21%
Immunofluorescence
14%
Binding Affinity
14%
Western Blot
7%
Molecular Weight
7%
Xenograft
7%
Deglycosylation
7%
Dynamics
7%
In Vitro
7%